Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients

Annals of Thoracic Surgery

Volumn 64, Issue 6, 1997, Pages 1686-1693

  D'Ambra, Michael N ^a   Gray, Richard J ^b   Hillman, Robert ^c   Jones, James W ^d   Kim, Hugh C ^e   Rawitscher, Robert ^f   Schnaper, Harold ^g   Szymanski, Irma ^h   Vlahakes, Gus J ^a   Kaplan, David ⁱ   Lynch, Karen E ^a   Guilfoyle, Mary ^j   Abels, Robert I ^j  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f TOLEDO HOSPITAL   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j R W JOHNSON PHARMACEUTICAL RES I   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HUMAN SERUM ALBUMIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIESIS; FEMALE; FEVER; HEART ARRHYTHMIA; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; EPOETIN ALFA; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED;

EID: 0031406905     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(97)00839-4     Document Type: Article

References (22)

1. Øvrum E, Holen EÅ, Abdelnoor M, Øystese R. Conventional blood conservation techniques in 500 consecutive coronary artery bypass operations. Ann Thorac Surg. 52:1991;500-505.
2. Love TR, Hendren WG, O'Keefe DD, Daggett WM. Trans- fusion of predonated autologous blood in elective cardiac surgery. Ann Thorac Surg. 43:1987;508-512.
3. Murphy PJ, Connery C, Hicks GL, Blumberg N. Allogeneic blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. J Thorac Cardiovasc Surg. 104:1992;1092-1099.
4. D'Ambra MN. Use of erythropoietin in open heart surgery. Perfusion. 8:1993;13-20.
5. Surgenor DM, Wallace EL, Churchill WH, Hao SHS, Chapman RH, Collins JJ. Red cell transfusions in coronary artery bypass surgery (DRGs 106 and 107). Transfusion. 32:1992;458-464.
6. Goodnough LT, Johnston MFM, Toy PTCY. The variability of transfusion practice in coronary artery bypass surgery. JAMA. 256:1991;86-98.
7. Sloand EM, Pitt E, Klein HG. Safety of the blood supply. JAMA. 274:1995;1368-1373.
8. Flaharty KK, Caro J, Erslev A, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther. 47:1990;557-564.
9. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 321:1989;158-163.
10. Miller CB, Platanias LC, Mills SR, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst. 84:1992;98-103.
11. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 322:1990;1488-1493.
12. Watanabe Y, Fuse K, Konishi T, et al. Autologous blood transfusion with recombinant human erythropoietin in heart operations. Ann Thorac Surg. 51:1991;767-772.
13. De Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC. Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. Am J Orthopedics. 25:1996;533-542.
14. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of Epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthopedics. 25:1996;544-552.
15. Gaudiani VA, Mason HDW. Preoperative erythropoietin in Jehovah's Witnesses who require cardiac procedures. Ann Thorac Surg. 51:1991;823-824.
16. Kyo S, Omoto R, Hirashima K, Eguchi S, Fujita T. Effect of human recombinant erythropoietin on reduction of homologous blood transfusion in open heart surgery. Circulation. 86:(Suppl):1992;413-418.
17. International classification of diseases; vols 1 and 2: Clinical modification. 9th rev.
18. The National Adverse Drug Reaction Directory of COSTART.
19. Jain U. Myocardial infarction during coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 6:1992;612-623.
20. Hannan EL, Kilburn H Jr, O'Donnell JF, Lukacik G, Shields EP. Adult open-heart surgery in New York State. JAMA. 264:1990;2768-2774.
21. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with Epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood. 89:1997;411-418.
22. Hannan EL, Bernard HR, Kilburn HC, O'Donnell JF. Gender differences in mortality rates for coronary artery bypass surgery. Am Heart J. 123:1992;866-872.